Vrbanec D, Plestina S, Belev B, Unusić J, Pavlinić-Diminić V
Klinika za patofiziologiju Medicinskog fakulteta, KBC Zagreb.
Lijec Vjesn. 1999 Sep-Oct;121(9-10):296-301.
Bisphosphonates represent nowadays a standard therapy of tumor induced hypercalcemia and are progressively more used in the treatment of tumor bone metastatic disease. Among several bisphosphonates, pamidronate is one of the most commonly used in clinical practice, so we also used it in succesful treatment of patients with breast cancer bone metastases. It has been shown that pamidronate reduces the frequency of hypercalcemia, bone pain and pathological fractures, although the mechanisms by which these effects are achieved are not completely clarified. Bisphosphonates are also important not only in treating patients with present metastases but also in prevention, or at least, delay of bone metastases onset. Recently, there are clinical trials examining the so called adjuvant therapy, that means the use of bisphosphonates in prevention of bone metastases in high risk breast cancer patients without distant metastases. In addition to breast cancer, multiple myeloma is another area of successful bisphosphonate application. In this paper we present some of the clinical results following the use of pamidronate in breast cancer- and hypernephroma-patients with hypercalcemia.
双膦酸盐如今是肿瘤诱导的高钙血症的标准治疗方法，并且在肿瘤骨转移疾病的治疗中使用得越来越多。在几种双膦酸盐中，帕米膦酸盐是临床实践中最常用的之一，因此我们也用它成功治疗了乳腺癌骨转移患者。已经表明，帕米膦酸盐可降低高钙血症、骨痛和病理性骨折的发生率，尽管实现这些效果的机制尚未完全阐明。双膦酸盐不仅在治疗现有转移患者方面很重要，而且在预防或至少延迟骨转移的发生方面也很重要。最近，有临床试验在研究所谓的辅助治疗，即使用双膦酸盐预防无远处转移的高危乳腺癌患者发生骨转移。除了乳腺癌，多发性骨髓瘤是双膦酸盐成功应用的另一个领域。在本文中，我们展示了在乳腺癌和肾细胞癌高钙血症患者中使用帕米膦酸盐后的一些临床结果。
